A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia (CARDEA-Plus)
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Zegocractin (Primary) ; Corticosteroids; Dexamethasone; Remdesivir; Tocilizumab
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Acronyms CARDEA-Plus
- Sponsors CalciMedica
- 18 Mar 2022 Planned initiation date changed from 1 Jan 2022 to 24 Jan 2022.
- 18 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jan 2022 New trial record